Cargando…
The Hippo Transducer YAP/TAZ as a Biomarker of Therapeutic Response and Prognosis in Trastuzumab-Based Neoadjuvant Therapy Treated HER2-Positive Breast Cancer Patients
BACKGROUND: We explored the therapeutic and prognostic effect of YAP/TAZ intensityinHER2-positive breast cancer patients. We also investigated the relationship between YAP/TAZ expression and Trastuzumab-resistance. METHODS: We collected clinicopathological information from 397 cases. We evaluated th...
Autores principales: | Yuan, Jia-qi, Ding, Nian-hua, Xiao, Zhi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481481/ https://www.ncbi.nlm.nih.gov/pubmed/32973536 http://dx.doi.org/10.3389/fphar.2020.537265 |
Ejemplares similares
-
The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy
por: Vici, Patrizia, et al.
Publicado: (2014) -
The Roles of Hippo Signaling Transducers Yap and Taz in Chromatin Remodeling
por: Hillmer, Ryan E., et al.
Publicado: (2019) -
Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapy
por: Vici, Patrizia, et al.
Publicado: (2016) -
The Hippo transducers TAZ/YAP and their target CTGF in male breast cancer
por: Benedetto, Anna Di, et al.
Publicado: (2016) -
The Hippo Pathway Transducers YAP1/TEAD Induce Acquired Resistance to Trastuzumab in HER2-Positive Breast Cancer
por: González-Alonso, Paula, et al.
Publicado: (2020)